CAMBRIDGE, Mass., Nov. 2 /PRNewswire/ -- Peptimmune, Inc., a privately
held biopharmaceutical company announced today the promotion of Thomas P.
Mathers, 38, from President to President and Chief Executive Officer. Mr.
Mathers has also been elected to the Board of Directors. Mathers succeeds
Robert Carpenter, former CEO, who will remain as Executive Chairman of the
Board.
"Peptimmune has rapidly grown in personnel and capabilities, and with
Tom's leadership, we have made significant progress on all of our product
development efforts," commented Chairman Bob Carpenter.
About Peptimmune Inc.
Peptimmune, Inc. is a privately held clinical stage biotechnology company
focused on utilizing both novel and proven technologies to improve the
therapeutic management of chronic autoimmune and metabolic disorders. The
company is developing second generation therapeutics that are expected to
result in safer and more effective products for obesity, multiple sclerosis,
rheumatoid arthritis and pemphigus vulgaris. Founded by a team of world class
scientists and led by an experienced management team, Peptimmune's mission is
to reduce the burden these diseases place on the individuals, their families
and the healthcare system. For additional information, visit the company's
website at http://www.peptimmune.com.
Contact:
Thomas P. Mathers, 617-715-8040 (President and Chief Executive Officer),
or tom.mathers@peptimmune.com
SOURCE Peptimmune Inc.
 back to top
Related links:
http://www.peptimmune.com
CONTACT:
Thomas P. Mathers, President and Chief
Executive Officer of Peptimmune, +1-617-715-8040,
tom.mathers@peptimmune.com
|
